Real-world experience in UK centres


Find out more about real-world experience in UK centres



DUPIXENT has an extensive Phase 3 clinical trial programme with improvements in lesion extent and severity, itch and quality-of-life1


Reimbursement

Learn about the reimbursement of DUPIXENT in England, Wales and Scotland.





Find out more


Safety Profile

Learn more about safety profile of DUPIXENT.






Find out more


Dosing

Learn more about how to administer DUPIXENT.






Find out more

    AD, atopic dermatitis; UK, United Kingdom.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
    3. Sears AV, et al. Br J Dermatol. 2021;184(4):755–757.
    4. Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Poster P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
    5. O’Driscoll D, et al. Dupilumab, an incoming treatment for adolescents with atopic dermatitis: experience from a tertiary eczema. Abstract PA01. Presented at the 99th British Association of Dermatologists Annual meeting, Liverpool, July 2–4 2019.
    6. Gardette E, et al. Real-world experience of dupilumab for the treatment of severe recalcitrant atopic dermatitis in a tertiary centre. Abstract O06. Presented at the 99th British Association of Dermatologists Annual meeting, Liverpool, July 2–4 2019.

MAT-IE-2101031(v4.0) | Date of preparation: February 2022